Compass Diversified (NYSE: CODI ) is an investment holding company that manages and owns controlling interests in several medium sized businesses across a variety of industries. It got slammed on May 8, dropping 62% onI am a private investor based out of Toronto, Canada and I have been investing since 2003. After 8 years in Corporate Finance with a Canadian Telecom company I have decided to dedicate myself full-time to the capital markets. I write on Seeking Alpha to demonstrate my financial analysis and wr ...

Company Participation in Investor Conferences - Cellebrite plans to participate in several investor conferences in May and June 2025, including the Craig-Hallum Institutional Investor Conference on May 28, TD Cowen 52 Annual Technology, Media & Telecom Conference on May 29, Bank of America 2025 Global Technology Conference on June 3, William Blair 45 Annual Growth Stock Conference on June 4, and D.A. Davidson Inaugural Consumer & Technology Conference on June 10 [1]. Executive Representation - The executives representing Cellebrite at these conferences will include Dana Gerner, Chief Financial Officer, and Andrew Kramer, Vice President of Investor Relations [1]. Conference Formats and Webcast Availability - The conferences will feature various formats, including 1x1 meetings and fireside chats, with specific presentation times noted for each event. Webcast links for the fireside chats and management presentations are available on Cellebrite's investor relations microsite [1][2]. Company Mission and Services - Cellebrite's mission is to enhance digital investigations and intelligence gathering to accelerate justice globally. The company offers an AI-powered Digital Investigation Platform that allows lawful access, collection, analysis, and sharing of digital evidence while preserving data privacy [3]. Client Base - Thousands of public safety organizations, intelligence agencies, and businesses utilize Cellebrite's digital forensic and investigative solutions, which are available through cloud, on-premises, and hybrid deployments [3]. Contact Information - Investor relations inquiries can be directed to Andrew Kramer, Vice President of Investor Relations, while media inquiries can be directed to Jackie Labrecque, Senior Manager of Content Strategy and Operations [4].

TORONTO, May 20, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announces that it has signed an agreement with a global pharmaceutical contract research organization to prepare an IND (Investigational New Drug) application package for Lucid-21-302 (Lucid-MS) with the US FDA. A successful IND application will allow Quan ...

SARASOTA, FL, May 14, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it has engaged Veloxity Labs, LLC for bioanalysis supporting the ongoing investigational new drug (IND)-enabling GLP (Good Laboratory Practice)-compliant toxicology and toxicokinetics study of its lead asset, SPC-15, an intranasal prophylactic treatment for post-traumatic stress ...

Group 1 - Iovance Biotherapeutics reported a significant decline in first quarter 2025 product revenue, totaling $49.3 million compared to $73.7 million in the previous quarter [2] - The company revised its full fiscal year 2025 total product revenue guidance from a range of $450 million - $475 million to $250 million - $300 million, indicating a reduction of over 40% at the midpoint [2] - The revenue guidance revision was attributed to recent launch dynamics of the T cell immunotherapy, Amtagvi® (lifileucel), which was launched in the U.S. in the first half of 2024 [2] Group 2 - Following the announcement of the financial results and guidance revision, Iovance's stock experienced a drop on unusually heavy trading volume [2] - Bragar Eagel & Squire, P.C. is investigating potential claims against Iovance on behalf of stockholders regarding possible violations of federal securities laws and unlawful business practices [1]

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Fluence Energy, Inc. due to a class action complaint alleging breaches of fiduciary duties by the board of directors during a specified class period [1] Group 1: Lawsuit Details - The lawsuit claims that during the class period, Fluence made false or misleading statements and failed to disclose critical information regarding its relationships with major revenue sources, Siemens AG and The AES Corporation [2] - Specific allegations include accusations from Siemens Energy regarding engineering failures and fraud, as well as inflated margins and revenue growth due to impending divestitures by Siemens and AES [2] - The lawsuit asserts that the defendants lacked a reasonable basis for their positive statements about Fluence's battery energy storage business and financial prospects, leading to investor damages when the truth emerged [2] Group 2: Contact Information - Long-term stockholders of Fluence are encouraged to reach out for more information regarding the claims or their rights, with contact details provided for Brandon Walker and Marion Passmore [3]

FDA Breakthrough Device Designation Awarded to AVIM Therapy FDA IDE Approved for Virtue SAB U.S. Pivotal Trial for Launch NEW HOPE, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced financial results for the first quarter ended March 31, 2025, and provided a business update highlighting continued regulatory m ...

NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Compass Diversified Holdings (“Compass” or the “Company”) (NYSE:CODI). The investigation concerns whether Compass and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] On May 7, 2025, after the markets closed, Compass filed a Form 8-K which stated that the Audit Committee of Board ...

Ferroglobe (GSM) Q1 2025 Earnings Call May 08, 2025 08:30 AM ET Speaker0 As a reminder, this conference call may be recorded. I would now like to turn the call over to Alex Rotonin, Ferroglobe's Vice President of Investor Relations. You may begin. Speaker1 Thanks, Nadia. Good morning, everyone, and thank you for joining Ferroglobe's first quarter twenty twenty five conference call. Joining me today are Marco Levi, our Chief Executive Officer and Beatrice Garcia Cos, our Chief Financial Officer. Before we ge ...

Core Viewpoint - Backblaze, Inc. is under investigation for potential violations of federal securities laws and unlawful business practices following a negative report from Morpheus Research that highlighted financial missteps and questionable accounting practices [1][2]. Group 1: Investigation and Legal Actions - Bragar Eagel & Squire, P.C. is investigating potential claims against Backblaze on behalf of its stockholders [1]. - The investigation is focused on whether Backblaze has engaged in unlawful business practices and violated federal securities laws [1]. - Stockholders who have suffered losses or have information regarding these claims are encouraged to contact the law firm [3]. Group 2: Financial Performance and Market Reaction - Backblaze's stock experienced a significant decline following the release of a critical report from Morpheus Research, which detailed alleged financial missteps since the company's IPO in November 2021 [2]. - The report accused Backblaze of questionable accounting practices, including financial manipulations and inflated forecasts [2]. - The stock price dropped during intraday trading on April 24, 2025, in response to the report [2].